Seite 1 von 5
Neuester Beitrag: 10.03.20 11:44
|Eröffnet am:||03.05.19 12:25||von: moneywork4.||Anzahl Beiträge:||108|
|Neuester Beitrag:||10.03.20 11:44||von: Vassago||Leser gesamt:||11.120|
|Seite: < 1 | 2 | 3 | 4 | 5 5 >|
Dieser Markt wächst allmählich mit einer konstanten CAGR von 3,8% im Prognosezeitraum 2019-2026. Hier sind nur wenige Namen der führenden Unternehmen aufgeführt - Foamix Pharmaceuticals Ltd., Allergan, Bausch Health, Sol-Gel Technologies Ltd., Bayer AG , Nestlé, PRUGEN, Merck & Co., Inc., AbbVie Inc., Unilever, Croda International, Colorescience, Inc., Perrigo, Aclaris Therapeutics, Inc., Lupine Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc, Dr Reddy's Laboratories Ltd., unter anderem Mylan NV.
Mein Tipp einfach komplett lesen.. Sehr Positiv..
Thomson Reuters StreetEventsNovember 9, 2019
Spring Forward With Aclaris Therapeutics, Inc. (ACRS)
By Nicola Day
November 8, 2019
Most of the analysts surveyed by Thomson/First Call think quite highly of Aclaris Therapeutics, Inc. 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $9 on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), which corresponds to 383.87% upside potential than its current market price of $1.86 and implies potential despite the recent advance in the price. However, their current target price has fallen from $17.33 a month ago and is down handily from the consensus target of $17.33 a quarter ago.
Aber viel potenzial..
With our sights set on discovery, Aclaris is currently exploring the kinome, a subset of the human genome that consists of a collection of approximately 518 protein kinases, one of the largest of all human gene families, and a key control point in cell behavior.
Classified into eight major groups based on their structural similarity to each other, kinases are key regulators of cell function for many cell processes. By transferring phosphates to other molecules, kinases can induce a cellular response to environmental cues. Dysregulation and/or mutations in kinases can disrupt normal cell signaling and lead to diseases ranging from diabetes to cancer, making them important targets for drug development.
Currently, there are a number of approved kinase inhibitors on the market, such as Xeljanz® (tofacitinib citrate), Gleevec® (imatinib mesylate), and Tarceva® (erlotinib). However, these drugs only target a small fraction of the kinome, with many clinically relevant kinases lacking validated inhibitors.
Were focused on the design and development of kinase inhibitors that target key enzymes involved in chronic inflammation, autoimmune disease, or the regulation of cancer growth, survival and metastasis.
Dec. 9, 2019 10:40 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor
Merck's $2.7B bid for ArQule is yet another example of Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK).
positive Phase1 Studiendaten bei ATI-450
Zahlen für 2019
"Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2019, will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential business development transactions or financing activities."